Nothing Special   »   [go: up one dir, main page]

Coiffier, 1995 - Google Patents

Fourteen years of high-dose CHOP (ACVB regimen): preliminary conclusions about the treatment of aggressive-lymphoma patients. Hamilton Fairley Award Lecture …

Coiffier, 1995

View PDF
Document ID
5184851093609428166
Author
Coiffier B
Publication year
Publication venue
Annals of oncology: official journal of the European Society for Medical Oncology

External Links

Snippet

Fourteen years of high-dose CHOP (ACVB regimen): preliminary conclusions about the treatment of aggressive-lymphoma patients. Hamilton Fairley Award Lecture, European Society for Medical Oncology Meeting, Lisbon, November 21, 1994 Fourteen years of high-dose …
Continue reading at www.sciencedirect.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR

Similar Documents

Publication Publication Date Title
Coiffier Fourteen years of high-dose CHOP (ACVB regimen): preliminary conclusions about the treatment of aggressive-lymphoma patients. Hamilton Fairley Award Lecture, European Society for Medical Oncology Meeting, Lisbon, November 21, 1994
Weil et al. Daunorubicin in the therapy of acute granulocytic leukemia
HK1031197A1 (en) Osmotic dosage form comprising first and second coats
PL321791A1 (en) Method of and compositions and sets of agents for enhancing oral biological availability of pharmaceutic agents
HUP0203238A3 (en) Drugs for the treatment of malignant tumours, process for their preparation and pharmaceutical compositions containing them
PL287844A1 (en) Method of obtaining an oraly administered composite medicine for treating interstinal inflamatory diseases
CA2138122A1 (en) Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma, stomach and breast cancer
Coleman et al. The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma
WO1999022722A3 (en) Use of macrolides for the treatment of cancer and macular degeneration
Lee et al. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (# 79-04)
WO2000008007A3 (en) Cyclopentabenzofuran derivatives and their use
Goodnick Nimodipine treatment of rapid cycling bipolar disorder.
TW338722B (en) On-line drug delivery system in extracorporeal therapy
HUP0100384A3 (en) Medicaments containing micronized benzopyrane and pyridopyrane drugs, use of them, and process for producing them
Biganzoli et al. The bigger the better?... or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer
Peters et al. Intermediate and high-dose cytosine arabinoside-containing regimens for induction and consolidation therapy for patients with acute lymphoblastic leukemia and lymphoblastic non-Hodgkin's lymphoma: the Leyden experience and review of the literature
NZ314488A (en) Anticancer medicaments containing alpha1-adrenoreceptor antagonist compounds
Hiddemann et al. New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only--a preliminary update of the German Low-Grade Lymphoma Study Group
Motzer et al. Paclitaxel in germ cell cancer
Bezwoda et al. A randomized comparative study of cyclophosphamide, vincristine, doxorubicin, and prednisolone and cyclophosphamide, vincristine, mitoxantrone, and prednisolone regimens in the treatment of intermediate-and high-grade lymphoma with 8 years' follow-up
Dottino et al. Clinical trial of etoposide and cisplatin as salvage therapy in advanced ovarian carcinoma
Fisher et al. Adjuvant chemotherapy for breast cancer: an overview of NSABP findings
Watanabe Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral UFT (uracil/tegafur) versus six-cycle CMF (cyclophosphamide/methotrexate/5-fluorouracil) in high-risk node-negative breast cancer patients
Shepherd et al. Phase I trial of granulocyte-macrophage colony-stimulating factor with high-dose cisplatin and etoposide for treatment of small-cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group
AR109456A2 (en) USE OF ET743 FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A HUMAN PATIENT AFFECTED BY CANCER THROUGH COMBINATION THERAPY